PHARM.AS stock trades at EUR 1.33 in pre-market trade on 07 Mar 2026 as investors brace for an earnings release on 12 Mar 2026. Volume is elevated at 10,536,744 shares and the price is down -1.55% on the day. Expect the report to focus on RUCONEST sales, Joenja commercialization progress, and guidance for 2026 in EURONEXT-listed Pharming Group N.V. (Europe). We flag valuation, cash flow and clinical readouts as the main drivers for near-term moves.

PHARM.AS stock earnings preview and key dates

Pharming Group (PHARM.AS) will report results on 12 Mar 2026 after market hours; the company lists the announcement time as 16:30 UTC. Key items to watch in the earnings report are RUCONEST revenue trends, Joenja (leniolisib) uptake, margin progression, and any update on Novartis or Orchard collaboration milestones. Analysts and traders will watch guidance and commentary in EUR for 2026, since topline growth and product mix will influence short-term trading in the EURONEXT market.

Financials and valuation snapshot for PHARM.AS stock

At EUR 1.33 the market capitalisation stands near EUR 926.60M with 696,688,239 shares outstanding. Trailing EPS is -0.01, so the PE ratio is not meaningful for valuation assessment today. Key multiples: Price/Sales 2.97, Price/Book 3.90, and EV/EBITDA 24.01 (TTM metrics). Liquidity and solvency look solid with a current ratio 3.16 and debt/equity 0.49, while operating cash flow per share is 0.08 EUR. These figures frame expectations: the company shows positive free cash flow conversion but is priced for growth and clinical execution.

Meyka AI rates PHARM.AS with a score out of 100 and technical outlook

Meyka AI rates PHARM.AS with a score out of 100: 68.86 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show mild weakness ahead of earnings: RSI 39.76 (below neutral), MACD roughly flat, and Bollinger Bands at 1.30–1.45 EUR. The 50-day average is EUR 1.47 and the 200-day average is EUR 1.24, so the stock sits between short and long-term trend measures. Traders should note elevated relative volume and a short-term oversold CCI signal.

Earnings risks and catalysts for PHARM.AS stock

Primary catalysts are RUCONEST sales momentum and commercial progress for Joenja; any clinical or regulatory updates will move sentiment. Risks into the print include weaker-than-expected US pricing or reimbursement changes, slower uptake of leniolisib, and margin pressure from SG&A. Given biotech sector volatility in Europe, headline clinical news or partnership updates can drive double-digit intraday moves in PHARM.AS stock. Maintain position sizing discipline ahead of binary events.

Price targets and Meyka AI’s PHARM.AS stock forecast

Meyka AI’s forecast model projects a quarterly target EUR 1.54 and a 12-month target EUR 2.04. Compared with the current price EUR 1.33, the 12-month projection implies an upside of 53.13%. Short-term traders may reference the monthly model level EUR 1.19 as a nearer support target. Forecasts are model-based projections and not guarantees; outcomes will hinge on the 12 Mar earnings detail and upcoming commercial milestones.

Trading view and short-term strategy for PHARM.AS stock

Pre-market positioning should balance upside from the 12 Mar report against binary downside risk. For risk-managed exposure consider staggered entries and set stops around EUR 1.10–1.20 for tactical trades. Options traders can target a collar if they hold shares, while momentum players should wait for volume-confirmed moves above EUR 1.47 (50-day MA) for conviction. Use the Meyka AI page for live updates and real-time signals: Meyka PHARM.AS page.

Final Thoughts

PHARM.AS stock trades at EUR 1.33 in pre-market on 07 Mar 2026 as the market positions for the 12 Mar 2026 earnings release. Our analysis highlights a mixed fundamental picture: solid current liquidity and positive cash flow metrics versus valuation that prices growth and execution. Meyka AI’s model projects EUR 2.04 in 12 months, implying +53.13% from today’s price; Meyka AI assigns a 68.86 / Grade B (HOLD) based on sector and company metrics. Investors should treat the forecast as a model projection, not a guarantee, and watch RUCONEST sales, Joenja commercialization, and partnership updates for immediate impact. For traders, manage size around binary event risk and prefer confirmed volume breakouts above EUR 1.47 for bullish conviction in the EURONEXT-listed Pharming Group N.V.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.